🔗 Share this article

As the United States continues making historic adjustments to its vaccine recommendations, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by expressing skepticism about Covid shots throughout the global health crisis and has zeroed in on possible fatalities following COVID-19 vaccination in her short position at the FDA.

Planned Shifts to Childhood Vaccine Program

Agency leaders planned to unveil sweeping revisions to the childhood vaccine schedule in December, aligning the US with Denmark’s national calendar, it is understood – a significant shift that would place the US at odds with a large portion of the international standard with little proof for benefit. The planned update has been pushed back until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to present at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth individual to lead the office this calendar year.

A Shift at the Regulatory Body

The acting appointment might represent a closer partnership between the drug and vaccine branches as Høeg and Prasad consolidate power at the agency – and it signals a renewed priority upon dismantling already-approved vaccines at the FDA.

Høeg has often pushed for discontinuing certain childhood immunization guidelines in the US to become more like Denmark's approach, a country with comprehensive healthcare and a number of inhabitants approximately the population of the state of Wisconsin.

To date statements, she has persisted in emphasizing on immunizations – usually the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Concerns Over Expertise

Høeg has little discernible track record in pharmaceutical research, oversight or management, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and CBER since spring.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, stated Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in managing a major agency. She lacks background in drug approvals.”

Previous commissioners of CBER would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who led CBER have had.”

CDER has an enormous range of responsibilities at the agency, the former commissioner emphasized.

“Many people just focuses on the innovative therapies, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and so forth, and every single one must be supervised,” Woodcock noted. “The thing you neglect, that’s the thing that I always told people is going to bite you.”

There is also, a significant leadership aspect to the role, which manages over 5,000 personnel. “It’s a massive leadership role, if you execute it properly,” the former official said.

Response and Disputed Initiatives

Regarding concerns about Høeg’s qualifications and whether this appointment indicates increased cooperation among regulatory chiefs on vaccines, a press secretary stated that the “inquiries stem from incorrect assumptions”.

“This background aligns with the duties of her job,” the official said, noting the period Høeg spent advising the agency head on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg takes over the commissioner’s new expedited review system, a controversial expedited medication authorization process that allegedly worried her predecessors. “By what process are these medications being chosen for this fast-track system? Who makes the decisions?” Howard said. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

Broadly speaking, he stated, “the Food and Drug Administration appears to be shifting towards more relaxed rules of most medications, except for vaccines.”

Established Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if troubling, track record, critics observe. She released a research paper using unconfirmed crowd-sourced reports to assess the incidence of myocarditis following COVID-19 immunization. She advised the state of Florida top health official Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are more dangerous than they are.

Part of her “desired changes” for the current government included revising rules for recently developed shots and ending “unnecessary” immunizations, she remarked following the vote on a online show. At the agency, Dr. Høeg has reportedly proposed barring adolescent males from obtaining COVID-19 vaccines.

“She’s an thorough ideologue who starts off with her beliefs and tailors the evidence to fit the evidence in a highly misleading, fraudulent manner,” Howard argued.

Taking Control and a “Revenge Tour”

Høeg aligned with other dissenters, {like|